Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Engineered stem cells can home in on tumors and deliver drug payload in mice

03.11.2004


Researchers at The University of Texas M. D. Anderson Cancer Center have perfected a delivery system for anticancer treatment that zeroes in on a tumor and becomes part of its supporting tissue. This new "cellular vehicle" then pumps drugs directly into cancer cells to disable them, but leaves normal tissue alone.



They say their study, published in the Journal of the National Cancer Institute, is a proof of principle, conducted in mice, that shows this kind of strategy could be promising when developed for human use. "This is the most effective homing strategy seen to date, much better than any viral delivery strategy tested so far," says Michael Andreeff, M.D., Ph.D., professor in the Departments of Blood and Marrow Transplantation and Leukemia. "It is remarkable that these cells can find tumors wherever they are and become part of them."

The new approach uses human mesenchymal stem cells (MSC), the body’s natural tissue regenerators. Tissue that is injured sends signals to these unspecialized, progenitor cells, and they, in turn, migrate to the damage and morph into whatever kind of tissue - bone, fat, muscle, cartilage, tendons - is needed to repair the wound. Tumors, however, are "never-healing wounds" that also signal these stem cells, and then use them to help build up "stromal," or connective tissue, that structurally supports and nurtures tumor growth, says Andreeff. "Tumors constantly remodel their architecture with the help of these special stem cells."


Andreeff, first author Matus Studeny, M.D., who was a research fellow in Andreeff’s lab, and a group of six other researchers turned the tables on cancer, taking advantage of a tumor’s ability to attract these stem cells. They designed a novel delivery system by isolating a small quantity of MSC from bone marrow, and then greatly expanded those cells in the lab. The researchers then used a virus to deliver a particular gene that has therapeutic action against cancer into the stem cells. When given back through an intravenous injection, the millions of engineered mesenchymal progenitor cells engraft where the tumor environment is signaling them, and then activate the therapeutic gene.

The team has already tested the system in a number of different solid cancers, as well as in leukemia, to deliver different "payloads," but in this study, they looked at whether MSC engineered to carry interferon beta could treat mice that were implanted with human breast cancer or human melanoma. Interferon beta can inhibit cancer growth in laboratory tests, but is excessively toxic and short-lived when used at high doses as a therapy in patients, says Andreeff. The team tested whether MSC engineered to express an interferon beta gene could provide a sustained and targeted effect directly to cancer cells.

For each of the two cancer types, the researchers tested three groups of mice against each other: one was an untreated control group; another was injected with interferon beta daily under the skin for three weeks; and the third received three weekly doses of intravenous MSC engineered to express the interferon beta payload.

They found that the MSC cellular vehicles readily grafted themselves into the tumor stroma and proliferated. The cells also delivered its drug over a long period of time, significantly improving survival of the mice. Specifically, mice whose breast cancer was treated with MSC survived 60 days compared to 41 days in the mice injected with interferon beta, and 37 days in untreated mice. Mice with melanoma that were treated with MSC more than doubled their survival (73.5 days) compared with treated mice (32 days) and untreated mice (30 days). Andreeff says that use of interferon beta therapy in this study is less important than proof that the MSC strategy works. "The most important discovery here is that these cells are indeed homing into tumors and are capable of delivering an anticancer payload," he says. "Now we can work to test a number of different therapeutic payloads to see which works best."

He speculates that this new tactic in the war on cancer might work particularly well after patients are treated with radiation or chemotherapy, because those therapies damage cancer cells, which would then be in critical need of MSC. Andreeff hopes that this new homing strategy might offer a novel way to treat cancer that has spread. "This drug delivery system is attracted to cancer cells no matter what form they are in or where they are," he says.

Heather Sessions | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Life Sciences:

nachricht Rainbow colors reveal cell history: Uncovering β-cell heterogeneity
22.09.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden

nachricht The pyrenoid is a carbon-fixing liquid droplet
22.09.2017 | Max-Planck-Institut für Biochemie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

Hope to discover sure signs of life on Mars? New research says look for the element vanadium

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>